A 52-Week, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Mul
Research payments
$768,686
Through program year 2025, $768,686 in research payments was reported against A 52-Week, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Mul, across 127 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $231,293 | 53 |
| 2024 | Research | $300,949 | 44 |
| 2023 | Research | $149,621 | 22 |
| 2022 | Research | $86,824 | 8 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Michael Wechsler Denver, CO Named on 42 payments
- Ulrich Specks Rochester, MN Named on 22 payments
- Sebastian Sattui Cortes Pittsburgh, PA Named on 17 payments
- Michael Bubb Gainesville, FL Named on 9 payments
- Lindsay Lally New York, NY Named on 7 payments
- Leslie Ranken Charlotte, NC Named on 6 payments
- Basil Kahwash Columbus, OH Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.